Invention Grant
US07927795B2 Gene expression profiling in primary ovarian serous papillary tumors and normal ovarian epithelium
有权
原发性卵巢浆液性乳头状瘤和正常卵巢上皮的基因表达谱
- Patent Title: Gene expression profiling in primary ovarian serous papillary tumors and normal ovarian epithelium
- Patent Title (中): 原发性卵巢浆液性乳头状瘤和正常卵巢上皮的基因表达谱
-
Application No.: US10862517Application Date: 2004-06-07
-
Publication No.: US07927795B2Publication Date: 2011-04-19
- Inventor: Alessandro D. Santin
- Applicant: Alessandro D. Santin
- Applicant Address: US AK Little Rock
- Assignee: Board of Trustees of the University of Arkansas
- Current Assignee: Board of Trustees of the University of Arkansas
- Current Assignee Address: US AK Little Rock
- Agent Benjamin Aaron Adler
- Main IPC: C12Q1/68
- IPC: C12Q1/68 ; C12P19/34 ; C07H21/02 ; C07H21/04
Abstract:
Gene expression profiling and hierarchal clustering analysis readily distinguish normal ovarian epithelial cells from primary ovarian serous papillary carcinomas. Laminin, tumor-associated calcium signal transducer 1 and 2 (TROP-1/Ep-CAM; TROP-2), claudin 3, claudin 4, ladinin 1, S100A2, SERPIN2 (PAI-2), CD24, lipocalin 2, osteopontin, kallikrein 6 (protease M), kallikrein 10, matriptase and stratifin were found among the most highly overexpressed genes in ovarian serous papillary carcinomas, whereas transforming growth factor beta receptor III, platelet-derived growth factor receptor alpha, SEMACAP3, ras homolog gene family, member I (ARHI), thrombospondin 2 and disabled-2/differentially expressed in ovarian carcinoma 2 (Dab2/DOC2) were significantly down-regulated. Therapeutic strategy targeting TROP-1/Ep-CAM by monoclonal chimeric/humanized antibodies may be beneficial in patients harboring chemotherapy-resistant ovarian serous papillary carcinomas.
Public/Granted literature
- US20050048535A1 Gene expression profiling in primary ovarian serous papillary tumors and normal ovarian epithelium Public/Granted day:2005-03-03
Information query
